A double blind, placebo controlled, parallel group study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of PF-00915275 [PF-915275] after oral administration to subjects with type 2 diabetes mellitus for 4 weeks
Phase of Trial: Phase I/II
Latest Information Update: 03 Jan 2008
At a glance
- Drugs PF 915275 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Sponsors Pfizer
- 03 Jan 2008 Status changed from in progress to discontinued according to ClinicalTrials.gov.
- 17 Aug 2007 Status changed from recruiting to in progress.
- 20 Feb 2007 New trial record.